Presurgical short term treatment of uterine fibroids with different doses of cetrorelix acetate: a double-blind, placebo-controlled multicenter study.

Engel JB, Audebert A, Frydman R, Zivny J, Diedrich K

European journal of obstetrics, gynecology, and reproductive biology22 Aug 2006Cited by 20 (Europe PMC)

PMID16930803DOI10.1016/j.ejogrb.2006.07.018PepBankPUB-16930803

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanRandomized controlled trialEfficacy outcome
In women with uterine fibroids, uterine volume fell 15.6+/-20.2% with 4 x 5 mg cetrorelix versus 5.1+/-32.1% with placebo.
In plain wordsIn women with fibroids, uterine volume fell 15.6% with 4 x 5 mg cetrorelix versus 5.1% with placebo.
Peptide
Cetrorelix
Outcome
DecreaseUterine volume reduction on day 29
Study
n: not reported in source
Comparator
Placebo
Analysis
Primary
Outcome group
Tumor growth · Reproductive and sexual health
Studied dose
5 mg on days 1, 8, 15 and 22 · 4 weeksAs given in this study (human).
Measurements
Mean uterine volume reduction, day 29
15.6%
cetrorelix 4 x 5 mg (SD 20.2)
Mean uterine volume reduction, day 29
5.1%
placebo (SD 32.1)
Source sentences
Summary
Mean (+/-S.D.) reduction of uterine volume on day 29 (MRI scan) was 5.1+/-32.1% with placebo, 15.6+/-20.2% with 4 x 5 mg, 15.4+/-34.6% with 4 x 10 mg and 0.6+/-30.6% with 2 x 10 mg cetrorelix.
4 context sentences(design, population, supporting numbers)
Summary · context
Randomized, double-blind, placebo-controlled study.
Summary · context
Patients were 109 premenopausal women, with at least one uterine fibroid, more than 4 cm in diameter.
Summary · context
Groups 1-3 received placebo, 5 and 10 mg of cetrorelix on days 1, 8, 15 and 22, respectively group 4 received 10mg of cetrorelix on days 1 and 15.
Summary · context
The main outcome measure was the reduction of uterine volume on day 29 and response, defined as >30% size reduction.
Report a problemFND-1693080301
02HumanRandomized controlled trialEfficacy outcome
In women with uterine fibroids, uterine volume fell 15.4+/-34.6% with 4 x 10 mg cetrorelix versus 5.1+/-32.1% with placebo.
In plain wordsIn women with fibroids, uterine volume fell 15.4% with 4 x 10 mg cetrorelix versus 5.1% with placebo.
Peptide
Cetrorelix
Outcome
DecreaseUterine volume reduction on day 29
Study
n: not reported in source
Comparator
Placebo
Analysis
Primary
Outcome group
Tumor growth · Reproductive and sexual health
Studied dose
10 mg on days 1, 8, 15 and 22 · 4 weeksAs given in this study (human).
Measurements
Mean uterine volume reduction, day 29
15.4%
cetrorelix 4 x 10 mg (SD 34.6)
Mean uterine volume reduction, day 29
5.1%
placebo (SD 32.1)
Source sentences
Summary
Mean (+/-S.D.) reduction of uterine volume on day 29 (MRI scan) was 5.1+/-32.1% with placebo, 15.6+/-20.2% with 4 x 5 mg, 15.4+/-34.6% with 4 x 10 mg and 0.6+/-30.6% with 2 x 10 mg cetrorelix.
4 context sentences(design, population, supporting numbers)
Summary · context
Randomized, double-blind, placebo-controlled study.
Summary · context
Patients were 109 premenopausal women, with at least one uterine fibroid, more than 4 cm in diameter.
Summary · context
Groups 1-3 received placebo, 5 and 10 mg of cetrorelix on days 1, 8, 15 and 22, respectively group 4 received 10mg of cetrorelix on days 1 and 15.
Summary · context
The main outcome measure was the reduction of uterine volume on day 29 and response, defined as >30% size reduction.
Report a problemFND-1693080302
03HumanRandomized controlled trialEfficacy outcome
In women with uterine fibroids, volume reduction was smaller with 2 x 10 mg cetrorelix: 0.6+/-30.6% versus 5.1+/-32.1% with placebo.
In plain wordsIn women with fibroids, volume reduction was smaller with 2 x 10 mg cetrorelix: 0.6% versus 5.1% with placebo.
Peptide
Cetrorelix
Outcome
DecreaseUterine volume reduction on day 29
Study
n: not reported in source
Comparator
Placebo
Analysis
Primary
Outcome group
Tumor growth · Reproductive and sexual health
Studied dose
10 mg on days 1 and 15 · 4 weeksAs given in this study (human).
Measurements
Mean uterine volume reduction, day 29
0.6%
cetrorelix 2 x 10 mg (SD 30.6)
Mean uterine volume reduction, day 29
5.1%
placebo (SD 32.1)
Source sentences
Summary
Mean (+/-S.D.) reduction of uterine volume on day 29 (MRI scan) was 5.1+/-32.1% with placebo, 15.6+/-20.2% with 4 x 5 mg, 15.4+/-34.6% with 4 x 10 mg and 0.6+/-30.6% with 2 x 10 mg cetrorelix.
4 context sentences(design, population, supporting numbers)
Summary · context
Randomized, double-blind, placebo-controlled study.
Summary · context
Patients were 109 premenopausal women, with at least one uterine fibroid, more than 4 cm in diameter.
Summary · context
Groups 1-3 received placebo, 5 and 10 mg of cetrorelix on days 1, 8, 15 and 22, respectively group 4 received 10mg of cetrorelix on days 1 and 15.
Summary · context
The main outcome measure was the reduction of uterine volume on day 29 and response, defined as >30% size reduction.
Report a problemFND-1693080303
04HumanRandomized controlled trialEfficacy outcome
In women with uterine fibroids, response was significantly higher with 4 x 10 mg cetrorelix: 42.3% versus 11.1% with placebo (p<0.05).
In plain wordsIn women with fibroids, response was higher with 4 x 10 mg cetrorelix: 42.3% versus 11.1% with placebo.
Peptide
Cetrorelix
Outcome
IncreaseResponse exceeding 30% size reduction
Study
n: not reported in source
Comparator
Placebo
Analysis
Primary
Outcome group
Tumor growth · Reproductive and sexual health
Studied dose
10 mg on days 1, 8, 15 and 22 · 4 weeksAs given in this study (human).
Measurements
Response (>30% size reduction)
42.3%
cetrorelix 4 x 10 mg
Response (>30% size reduction)
11.1%
placebo
Source sentences
Summary
Significant response versus placebo (p<0.05) occurred in the 4 x 10 mg group (42.3% versus 11.1%)
4 context sentences(design, population, supporting numbers)
Summary · context
The main outcome measure was the reduction of uterine volume on day 29 and response, defined as >30% size reduction.
Summary · context
Randomized, double-blind, placebo-controlled study.
Summary · context
Patients were 109 premenopausal women, with at least one uterine fibroid, more than 4 cm in diameter.
Summary · context
Groups 1-3 received placebo, 5 and 10 mg of cetrorelix on days 1, 8, 15 and 22, respectively group 4 received 10mg of cetrorelix on days 1 and 15.
Report a problemFND-1693080304

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.